Drugs / AP707
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05267769 | Mar → Apr 2022 | — | CannaXan GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267769 ↗ |
| Route | Other | “AP707 single dose oromucosal application” NCT05267769 ↗ |